Daiichi Sankyo Co Ltd
TSE:4568

Watchlist Manager
Daiichi Sankyo Co Ltd Logo
Daiichi Sankyo Co Ltd
TSE:4568
Watchlist
Price: 4 336 JPY -1.36% Market Closed
Market Cap: 8.4T JPY
Have any thoughts about
Daiichi Sankyo Co Ltd?
Write Note
Daiichi Sankyo Co Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

Daiichi Sankyo Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Daiichi Sankyo Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Daiichi Sankyo Co Ltd
TSE:4568
Current Portion of Long-Term Debt
¥400m
CAGR 3-Years
-73%
CAGR 5-Years
-60%
CAGR 10-Years
-43%
Takeda Pharmaceutical Co Ltd
TSE:4502
Current Portion of Long-Term Debt
¥624.1B
CAGR 3-Years
43%
CAGR 5-Years
29%
CAGR 10-Years
14%
Otsuka Holdings Co Ltd
TSE:4578
Current Portion of Long-Term Debt
¥191.2B
CAGR 3-Years
57%
CAGR 5-Years
20%
CAGR 10-Years
9%
S
Shionogi & Co Ltd
TSE:4507
Current Portion of Long-Term Debt
¥3.3B
CAGR 3-Years
0%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Current Portion of Long-Term Debt
¥307.3B
CAGR 3-Years
43%
CAGR 5-Years
47%
CAGR 10-Years
45%
No Stocks Found

Daiichi Sankyo Co Ltd
Glance View

Market Cap
8.2T JPY
Industry
Pharmaceuticals

Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth. The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.

Intrinsic Value
5 333.41 JPY
Undervaluation 19%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Daiichi Sankyo Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
400m JPY

Based on the financial report for Sep 30, 2024, Daiichi Sankyo Co Ltd's Current Portion of Long-Term Debt amounts to 400m JPY.

What is Daiichi Sankyo Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-43%

Over the last year, the Current Portion of Long-Term Debt growth was 1%. The average annual Current Portion of Long-Term Debt growth rates for Daiichi Sankyo Co Ltd have been -73% over the past three years , -60% over the past five years , and -43% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.